TRYVIO (aprocitentan) in the US and JERAYGO in Europe present significant market potential as novel therapies for patients with hypertension inadequately controlled by existing treatments. TRYVIO ...

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

In pulmonary hypertension, a combination of metabolic and mechanical dysfunction leads to irreversible vascular damage.

Aprocitentan, on top of background therapy, showed clinically meaningful and durable blood pressure (BP) reduction and a decrease in proteinuria ...

Mendelian randomization (MR) represents a valuable methodology to address the causal relationships between an exposure and an ...

None of them focused specifically on adherence to pharmacological therapy for hypertension in Portugal. Considering the high prevalence of non-adherence and its location-specific aspects, the priority ...

New research reveals that lower proportions of specific sleep stages are associated with reduced brain volume in regions vulnerable to the development of Alzheimer's disease over time. Results show ...

Image: Adobe Stock “We know aldosterone plays an outsize role in CVD and in hypertension in general,” Luke J. Laffin, MD, co-director of the Center for Blood Pressure Disorders at Cleveland ...

CHICAGO — The addition of lorundrostat, an investigational drug, to the treatment regimen of people with well-treated but uncontrolled and resistant hypertension could be beneficial, new data show.

The Advance-HTN trial showed that lorundrostat effectively lowered 24-hour SBP at 12 weeks among patients with uncontrolled and treatment-resistant hypertension vs. placebo. Participants at 103 U.S.